Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Patients with metastatic renal cell cancer (mRCC) are commonly treated with the tyrosine kinase inhibitor sunitinib, which blocks signalling from vascular endothelial growth factor (VEGF) - and platelet-derived growth factor-receptors, inhibiting development of new blood vessels. There are currently no predictive markers available to select patient...
Alternative Titles
Full title
Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0748aaf10fc64588805e2ac5a8b8518a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0748aaf10fc64588805e2ac5a8b8518a
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-020-06770-z
